Related Experiment Video

Updated: Oct 16, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

11.0K

Prostate cancer: Alternatively spliced mRNA transcripts in tumor progression and their uses as therapeutic targets

Ali Calderon-Aparicio1, Bi-Dar Wang1

  • 1Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD 21853, USA.

The International Journal of Biochemistry & Cell Biology
|October 15, 2021
PubMed

Insights

Aberrant RNA splicing drives prostate cancer progression and treatment resistance. Targeting these splicing errors offers a promising therapeutic strategy to improve patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer is a leading cause of cancer death in men, with current therapies often failing due to treatment resistance and relapse.
  • Alternative RNA splicing, a process generating multiple protein variants from a single gene, is frequently dysregulated in cancer.
  • Aberrant mRNA splice variants are increasingly recognized as key drivers of prostate cancer malignancy.

Purpose of the Study:

  • To review the oncogenic roles of aberrant splicing in prostate cancer.
  • To explore the potential of splice variants as diagnostic markers and therapeutic targets.
  • To discuss strategies for targeting aberrant splicing mechanisms to overcome treatment resistance.

Main Methods:

  • Literature review and synthesis of existing research on RNA splicing in prostate cancer.
  • Analysis of studies investigating the functional impact of aberrant splice variants.
  • Discussion of current and emerging therapeutic approaches targeting splicing.

Main Results:

  • Aberrant splicing promotes prostate cancer by enhancing proliferation, metastasis, and anti-apoptosis.
  • Upregulated splice variants contribute significantly to treatment resistance and poor patient survival.
  • Splicing mechanisms represent viable targets for novel prostate cancer therapies.

Conclusions:

  • Aberrant RNA splicing is a critical factor in prostate cancer pathogenesis and therapeutic failure.
  • Targeting aberrant splicing pathways holds significant potential for improving diagnostic accuracy and treatment efficacy.
  • Developing therapies that correct splicing errors could overcome drug resistance and enhance clinical outcomes for prostate cancer patients.
Keywords:
Alternative splicingOligonucleotide therapiesSpliceosome assemblySplicing modulating proteinsTreatment resistance

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR

Published on: May 16, 2012

24.7K

Related Concept Videos

RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
57.8K
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
22.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K